Clinical Trials Update from NCI, December 2023: Tarlatamab Shows Promise for Some People with Small Cell Lung Cancer

https://content.govdelivery.com/accounts/USNIHNCI/bulletins/3816976?reqfrom=share Tarlatamab Shows Promise for Some People with Small Cell Lung Cancer Tarlatamab, a new type of targeted immunotherapy, shrank small cell lung cancer tumors in more than 30% of people in an early-stage clinical trial.